文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

重新审视非洲成人HIV者在抗逆转录病毒治疗时代的复方磺胺甲噁唑预防:一项随机对照临床试验

Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该随机对照试验在马拉维2个中心纳入1499名病毒载量检测不到且CD4>250/mm3的HIV成人,比较继续每日复方磺胺甲噁唑、停药改每周氯喹或停药。复方磺胺甲噁唑对死亡或WHO HIV/AIDS 3-4期事件的预防效果为22%(95%CI -14%-47%;加入2期事件后预防效果增至31%(3-51%;

要点

  • 免疫重建后继续复方磺胺甲噁唑未显著降低死亡或WHO 3-4期事件,但复合终点有获益。
  • 复方磺胺甲噁唑和氯喹均有效预防临床疟疾发作。
  • 撒哈拉以南非洲ART免疫重建成人因医疗可及性差建议继续复方磺胺甲噁唑预防。

核心结论

  • 马拉维ART后免疫重建的HIV成人继续复方磺胺甲噁唑预防,死亡和WHO HIV/AIDS 3-4期事件少于停药组,但未达统计学显著。
  • 复方磺胺甲噁唑预防可减少死亡加WHO HIV/AIDS 2-4期事件的复合终点。
  • 鉴于医疗可及性差和缺乏常规病毒载量监测,撒哈拉以南非洲ART后免疫重建成人应继续复方磺胺甲噁唑预防。

研究设计与样本

  • 在马拉维2个中心开展的随机对照临床试验,纳入1499名HIV成人。
  • 纳入标准为病毒载量检测不到且CD4计数>250/mm3。
  • 随机分为继续每日复方磺胺甲噁唑、停药改每周氯喹或停药三组。
  • 主要终点为死亡或WHO HIV/AIDS 3-4期事件,采用Cox比例风险模型在意向性治疗人群中分析。

临床怎么用

  • 在撒哈拉以南非洲,ART后免疫重建的HIV成人应继续复方磺胺甲噁唑预防。
  • 决策需考虑当地医疗可及性差和缺乏常规病毒载量监测的实际情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Daily co-trimoxazole is recommended for African adults living with human immunodeficiency virus (HIV) irrespective of antiretroviral treatment, immune status, or disease stage. Benefits of continued prophylaxis and whether co-trimoxazole can be stopped following immune reconstitution are unknown. METHODS: We conducted a randomized controlled trial at 2 sites in Malawi that enrolled adults with HIV with undetectable viral load and CD4 count of >250/mm3 and randomized them to continue daily co-trimoxazole, discontinue daily co-trimoxazole and begin weekly chloroquine, or discontinue daily co-trimoxazole. The primary endpoint was the preventive effect of co-trimoxazole prophylaxis against death or World Health Organization (WHO) HIV/AIDS stage 3-4 events, using Cox proportional hazards modeling, in an intention-to-treat population. RESULTS: 1499 adults were enrolled. The preventive effect of co-trimoxazole on the primary endpoint was 22% (95% CI: -14%-47%; P = .20) versus no prophylaxis and 25% (-10%-48%; P = .14) versus chloroquine. When WHO HIV/AIDS stage 2 events were added to the primary endpoint, preventive effect increased to 31% (3-51%; P = .032) and 32% (4-51%; P = .026), respectively. Co-trimoxazole and chloroquine prophylaxis effectively prevented clinical malaria episodes (3.8 and 3.0, respectively, vs 28/100 person-years; P < .001). CONCLUSIONS: Malawian adults with HIV who immune reconstituted on ART and continued co-trimoxazole prophylaxis experienced fewer deaths and WHO HIV/AIDS stage 3-4 events compared with prophylaxis discontinuation, although statistical significance was not achieved. Co-trimoxazole prevented a composite of death plus WHO HIV/AIDS stage 2-4 events. Given poor healthcare access and lack of routine viral load monitoring, co-trimoxazole prophylaxis should continue in adults on ART after immune reconstitution in sub-Saharan Africa. Clinical Trials Registration. NCT01650558.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Laurens MB, Mungwira RG, Nampota N, et al. Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial. Clin Infect Dis. 2021. PMID: 33744963. doi:10.1093/cid/ciab252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。